A Phase I/II Study of Xcellerated T Cells After Autologous Peripheral Blood Stem Cell Transplantation in Patients With Multiple Myeloma View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2002-

ABSTRACT

Patients will have immune cells collected and then expanded outside of the body. Patients will undergo standard treatment with high dose chemotherapy followed by peripheral blood stem cell transplantation. Three days following the transplant, patients will receive an infusion of a large number of expanded immune cells. The goal of the study will be to determine the safety as well as potential efficacy of this treatment. Detailed Description This Phase I/II clinical study is designed to examine the safety of Xcellerated T Cells, an activated, autologous T cell product, in study subjects undergoing an autologous peripheral blood stem cell transplant for the treatment of multiple myeloma. Thirty-five patients will be treated. Patients must have undergone induction therapy prior to study registration, and may not have progressed following induction therapy or any other prior therapy for myeloma. Patients will undergo a steady state leukapheresis (Xcellerate Leukapheresis) to obtain peripheral blood mononuclear cells that will be used to produce Xcellerated T Cells. During the Xcellerate Process, T cells will be activated and expanded ex vivo by co-stimulation with anti-CD3 and anti-CD28 monoclonal antibodies covalently attached to super-paramagnetic microbeads. While the Xcellerated T Cells are being produced at Xcyte Therapies, patients will be treated with a standard mobilization regimen consisting of cyclophosphamide and filgrastim (Neupogen; G-CSF), followed by a second leukapheresis for collection of peripheral blood stem cells. Patients will be treated with a standard high-dose chemotherapy regimen for multiple myeloma consisting of single agent melphalan (200mg/m2). Patients will then receive their peripheral blood stem cells followed by post-transplant filgrastim for neutrophil recovery. Three days (Day 3) following stem cell infusion, patients will receive a single dose Xcellerated T Cells. More... »

URL

https://clinicaltrials.gov/show/NCT00048464

Related SciGraph Publications

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3048", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "Patients will have immune cells collected and then expanded outside of the body. Patients will undergo standard treatment with high dose chemotherapy followed by peripheral blood stem cell transplantation. Three days following the transplant, patients will receive an infusion of a large number of expanded immune cells. The goal of the study will be to determine the safety as well as potential efficacy of this treatment.\n\nDetailed Description\nThis Phase I/II clinical study is designed to examine the safety of Xcellerated T Cells, an activated, autologous T cell product, in study subjects undergoing an autologous peripheral blood stem cell transplant for the treatment of multiple myeloma. Thirty-five patients will be treated. Patients must have undergone induction therapy prior to study registration, and may not have progressed following induction therapy or any other prior therapy for myeloma. Patients will undergo a steady state leukapheresis (Xcellerate Leukapheresis) to obtain peripheral blood mononuclear cells that will be used to produce Xcellerated T Cells. During the Xcellerate Process, T cells will be activated and expanded ex vivo by co-stimulation with anti-CD3 and anti-CD28 monoclonal antibodies covalently attached to super-paramagnetic microbeads. While the Xcellerated T Cells are being produced at Xcyte Therapies, patients will be treated with a standard mobilization regimen consisting of cyclophosphamide and filgrastim (Neupogen; G-CSF), followed by a second leukapheresis for collection of peripheral blood stem cells. Patients will be treated with a standard high-dose chemotherapy regimen for multiple myeloma consisting of single agent melphalan (200mg/m2). Patients will then receive their peripheral blood stem cells followed by post-transplant filgrastim for neutrophil recovery. Three days (Day 3) following stem cell infusion, patients will receive a single dose Xcellerated T Cells.", 
    "id": "sg:clinicaltrial.NCT00048464", 
    "keywords": [
      "phase I/II study", 
      "T cell", 
      "peripheral blood stem cell", 
      "multiple myeloma", 
      "patient", 
      "immune cell", 
      "body", 
      "standard treatment", 
      "high-dose chemotherapy", 
      "Transplant", 
      "infusion", 
      "large number", 
      "safety", 
      "potential efficacy", 
      "Phase I/II", 
      "clinical study", 
      "autologous T cell", 
      "study subject", 
      "induction therapy", 
      "registration", 
      "prior therapy", 
      "myeloma", 
      "steady state", 
      "leukapheresis", 
      "peripheral blood mononuclear cell", 
      "expanded ex vivo", 
      "co-stimulation", 
      "monoclonal antibody", 
      "therapy", 
      "mobilization", 
      "cyclophosphamide", 
      "Granulocyte Colony-Stimulating Factor", 
      "collection", 
      "single agent", 
      "post-transplant", 
      "neutrophil", 
      "stem cell", 
      "single dose"
    ], 
    "name": "A Phase I/II Study of Xcellerated T Cells After Autologous Peripheral Blood Stem Cell Transplantation in Patients With Multiple Myeloma", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT00048464"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:21", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00000.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.266102.1", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.21107.35", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.4367.6", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.50956.3f", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.239835.6", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.266100.3", 
        "type": "Organization"
      }
    ], 
    "startDate": "2002-10-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "https://doi.org/10.1097/00002371-200207000-00002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018831454"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nm0102-47", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018873794", 
          "https://doi.org/10.1038/nm0102-47"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00002371-200109000-00001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1060147044"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074975048", 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT00048464"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT00048464'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT00048464'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT00048464'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT00048464'


 

This table displays all metadata directly associated to this object as RDF triples.

81 TRIPLES      15 PREDICATES      62 URIs      46 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT00048464 schema:about anzsrc-for:3048
2 anzsrc-for:3103
3 schema:description Patients will have immune cells collected and then expanded outside of the body. Patients will undergo standard treatment with high dose chemotherapy followed by peripheral blood stem cell transplantation. Three days following the transplant, patients will receive an infusion of a large number of expanded immune cells. The goal of the study will be to determine the safety as well as potential efficacy of this treatment. Detailed Description This Phase I/II clinical study is designed to examine the safety of Xcellerated T Cells, an activated, autologous T cell product, in study subjects undergoing an autologous peripheral blood stem cell transplant for the treatment of multiple myeloma. Thirty-five patients will be treated. Patients must have undergone induction therapy prior to study registration, and may not have progressed following induction therapy or any other prior therapy for myeloma. Patients will undergo a steady state leukapheresis (Xcellerate Leukapheresis) to obtain peripheral blood mononuclear cells that will be used to produce Xcellerated T Cells. During the Xcellerate Process, T cells will be activated and expanded ex vivo by co-stimulation with anti-CD3 and anti-CD28 monoclonal antibodies covalently attached to super-paramagnetic microbeads. While the Xcellerated T Cells are being produced at Xcyte Therapies, patients will be treated with a standard mobilization regimen consisting of cyclophosphamide and filgrastim (Neupogen; G-CSF), followed by a second leukapheresis for collection of peripheral blood stem cells. Patients will be treated with a standard high-dose chemotherapy regimen for multiple myeloma consisting of single agent melphalan (200mg/m2). Patients will then receive their peripheral blood stem cells followed by post-transplant filgrastim for neutrophil recovery. Three days (Day 3) following stem cell infusion, patients will receive a single dose Xcellerated T Cells.
4 schema:keywords Granulocyte Colony-Stimulating Factor
5 Phase I/II
6 T cell
7 Transplant
8 autologous T cell
9 body
10 clinical study
11 co-stimulation
12 collection
13 cyclophosphamide
14 expanded ex vivo
15 high-dose chemotherapy
16 immune cell
17 induction therapy
18 infusion
19 large number
20 leukapheresis
21 mobilization
22 monoclonal antibody
23 multiple myeloma
24 myeloma
25 neutrophil
26 patient
27 peripheral blood mononuclear cell
28 peripheral blood stem cell
29 phase I/II study
30 post-transplant
31 potential efficacy
32 prior therapy
33 registration
34 safety
35 single agent
36 single dose
37 standard treatment
38 steady state
39 stem cell
40 study subject
41 therapy
42 schema:name A Phase I/II Study of Xcellerated T Cells After Autologous Peripheral Blood Stem Cell Transplantation in Patients With Multiple Myeloma
43 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT00048464
44 schema:sdDatePublished 2019-03-07T15:21
45 schema:sdLicense https://scigraph.springernature.com/explorer/license/
46 schema:sdPublisher N05e4dc3d680646f781a3fb24c2dcbfac
47 schema:sponsor https://www.grid.ac/institutes/grid.21107.35
48 https://www.grid.ac/institutes/grid.239835.6
49 https://www.grid.ac/institutes/grid.266100.3
50 https://www.grid.ac/institutes/grid.266102.1
51 https://www.grid.ac/institutes/grid.4367.6
52 https://www.grid.ac/institutes/grid.50956.3f
53 schema:startDate 2002-10-01T00:00:00Z
54 schema:subjectOf sg:pub.10.1038/nm0102-47
55 https://app.dimensions.ai/details/publication/pub.1074975048
56 https://doi.org/10.1097/00002371-200109000-00001
57 https://doi.org/10.1097/00002371-200207000-00002
58 schema:url https://clinicaltrials.gov/show/NCT00048464
59 sgo:license sg:explorer/license/
60 sgo:sdDataset clinical_trials
61 rdf:type schema:MedicalStudy
62 N05e4dc3d680646f781a3fb24c2dcbfac schema:name Springer Nature - SN SciGraph project
63 rdf:type schema:Organization
64 anzsrc-for:3048 schema:inDefinedTermSet anzsrc-for:
65 rdf:type schema:DefinedTerm
66 anzsrc-for:3103 schema:inDefinedTermSet anzsrc-for:
67 rdf:type schema:DefinedTerm
68 sg:pub.10.1038/nm0102-47 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018873794
69 https://doi.org/10.1038/nm0102-47
70 rdf:type schema:CreativeWork
71 https://app.dimensions.ai/details/publication/pub.1074975048 schema:CreativeWork
72 https://doi.org/10.1097/00002371-200109000-00001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1060147044
73 rdf:type schema:CreativeWork
74 https://doi.org/10.1097/00002371-200207000-00002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018831454
75 rdf:type schema:CreativeWork
76 https://www.grid.ac/institutes/grid.21107.35 schema:Organization
77 https://www.grid.ac/institutes/grid.239835.6 schema:Organization
78 https://www.grid.ac/institutes/grid.266100.3 schema:Organization
79 https://www.grid.ac/institutes/grid.266102.1 schema:Organization
80 https://www.grid.ac/institutes/grid.4367.6 schema:Organization
81 https://www.grid.ac/institutes/grid.50956.3f schema:Organization
 




Preview window. Press ESC to close (or click here)


...